Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 33, 2022 - Issue 8
Submit an article Journal homepage
132
Views
1
CrossRef citations to date
0
Altmetric
Articles

Evaluation of tolerability and efficacy of a topical emulgel containing nanoliposomal ruxolitinib phosphate in the treatment of mild atopic dermatitis: a before-after single group pilot study

Atefeh Naeimifara Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IranORCID Iconhttps://orcid.org/0000-0002-3958-4918View further author information
ORCID Icon,
Saman Ahmad Nasrollahib Center for Research & Training in Skin Diseases & Leprosy, Tehran University of Medical Sciences, Tehran, IranCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7384-6686View further author information
ORCID Icon,
Aniseh Samadib Center for Research & Training in Skin Diseases & Leprosy, Tehran University of Medical Sciences, Tehran, IranORCID Iconhttps://orcid.org/0000-0002-0134-429XView further author information
ORCID Icon,
Zeinab Aryanianc Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, IranORCID Iconhttps://orcid.org/0000-0001-7077-1458View further author information
ORCID Icon,
Hamid Akbari Javara Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IranORCID Iconhttps://orcid.org/0000-0003-4137-6939View further author information
ORCID Icon,
Mohammadreza Rouinia Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IranORCID Iconhttps://orcid.org/0000-0003-0412-8581View further author information
ORCID Icon,
Mansour Nassiri Kashanib Center for Research & Training in Skin Diseases & Leprosy, Tehran University of Medical Sciences, Tehran, IranORCID Iconhttps://orcid.org/0000-0002-4944-4863View further author information
ORCID Icon &
Alireza Firoozb Center for Research & Training in Skin Diseases & Leprosy, Tehran University of Medical Sciences, Tehran, IranORCID Iconhttps://orcid.org/0000-0001-7274-4840View further author information
ORCID Icon show all
Pages 3160-3164 | Received 14 Jun 2022, Accepted 05 Aug 2022, Published online: 05 Oct 2022

References

  • Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733–743.
  • Schmitt J, Bauer A, Meurer M. Atopic eczema in adulthood. Hautarzt. 2008;59(10):841–850.
  • Paller AS, McAlister RO, Doyle JJ, et al. Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment. Clin Pediatr. 2002;41(5):323–332.
  • Koblenzer CS, Koblenzer PJ. Chronic intractable atopic eczema: its occurrence as a physical sign of impaired parent–child relationships and psychologic developmental arrest: improvement through parent insight and education. Arch Dermatol. 1988;124(11):1673–1677.
  • Silverberg JI, Garg NK, Paller AS, et al. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Invest Dermatol. 2015;135(1):56–66.
  • Řeháková T, Stepanov A, Jirásková N. Steroid-induced glaucoma as a complication of atopic eczema local treatment. Cesk Slov Oftalmol. 2017;73(2):64–68.
  • Celakovská J, Bukač J. SCORAD reflects the duration of atopic dermatitis lesions. Indian J Dermatol. 2013;58(3):247.
  • Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–407.
  • Tanimoto A, Shinozaki Y, Yamamoto Y, et al. A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: comparison with conventional therapeutic agents. Exp Dermatol. 2018;27(1):22–29.
  • O'Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72(Suppl. 2):ii111–ii115.
  • Brumfiel CM, Patel MH, Severson KJ, et al. Ruxolitinib cream in the treatment of cutaneous lichen planus: a prospective, open-label study. J Invest Dermatol. 2022;142:2109–2116.e4.
  • Kim BS, Sun K, Papp K, et al. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study. J Am Acad Dermatol. 2020;82(6):1305–1313.
  • Kim BS, Howell MD, Sun K, et al. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol. 2020;145(2):572–582.
  • Naeimifar A, Ahmad Nasrollahi S, Akbari Javar H, et al. Designing a topical nanoliposomal formulation of ruxolitinib phosphate. Pharm Sci. 2022.
  • Alves de Medeiros K, Speeckaert R, Desmet E, et al. JAK3 as an emerging target for topical treatment of inflammatory skin diseases. PLOS One. 2016;11(10):e0164080.
  • Gerson S, Caimi P, Basem M, et al. Chapter 57 – pharmacology and molecular mechanisms of antineoplastic agents for hematologic malignancies. In: Hoffman R, Benz EJ, Silberstein LE, et al., editors. Hematology. 7th ed. Elsevier; 2018. p. 849–912.
  • Maghraby GM, Barry BW, Williams AC. Liposomes and skin: from drug delivery to model membranes. Eur J Pharm Sci. 2008;34(4–5):203–222.
  • Yazdanparast T, Yazdani K, Humbert P, et al. Biophysical measurements and ultrasonographic findings in chronic dermatitis in comparison with uninvolved skin. Indian J Dermatol. 2019;64(2):90–96.
  • Nasrollahi SA, Hassanzade H, Moradi A, et al. Safety assessment of tretinoin loaded nano emulsion and nanostructured lipid carriers: a non-invasive trial on human volunteers. Curr Drug Deliv. 2017;14(4):575–580.
  • Jenning V, Gysler A, Schafer-Koring M, et al. Vitamin a loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm. 2000;49(3):211–218.
  • Van Zuuren EJ, Fedorowicz Z, Arents BWM. Emollients and moisturisers for eczema: abridged Cochrane systematic review including GRADE assessments. Br J Dermatol. 2017;177(5):1256–1271.
  • Australasian Society of Clinical Immunology and Allergy [webpage on the Internet]. Atopic dermatitis (eczema). Brookvale, Australia: Australasian Society of Clinical Immunology and Allergy; 2016 [cited 2016 Jan 29]. Available from: https://www.allergy.org.au/images/pcc/
  • Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4):818–823.
  • Al-Adawiyah R, Putera AM, Astri L, et al. Determinant factors of recurrence atopic dermatitis symptoms in children: a cross-sectional study. Ann Med Surg. 2021;70:102847.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.